var data={"title":"Megestrol acetate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Megestrol acetate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6522?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=megestrol-acetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Megestrol acetate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=megestrol-acetate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Megestrol acetate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192314\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Megace ES;</li>\n      <li>Megace Oral [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192315\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Megace OS;</li>\n      <li>Megestrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192330\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Hormone;</li>\n      <li>\n        Appetite Stimulant;</li>\n      <li>\n        Progestin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192316\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Megace ES suspension is not equivalent to other formulations on a mg-per-mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anorexia or cachexia associated with AIDS:</b> Oral: Suspension: Initial: 625 mg daily (of the 125 mg/mL suspension) or 800 mg daily (of the 40 mg/mL suspension); daily doses of 400 mg to 800 mg have been found to be effective</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, advanced:</b> Oral: Tablet: 160 mg per day in divided doses of 40 mg 4 times daily for at least 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial cancer, advanced:</b> Oral: Tablet: 40 to 320 mg daily in divided doses for at least 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cancer-related cachexia (off-label use):</b> Oral: Doses ranging from 160 to 800 mg per day were effective in achieving weight gain, higher doses (&gt;160 mg) were associated with more weight gain (Beller 1997; Loprinzi 1990; Loprinzi 1993; Vadell 1998); based on a meta-analysis, an optimal dose has not been determined (Ruiz Garcia 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192317\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution; refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192318\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, the urinary excretion of megestrol acetate is substantial, use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317898\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192294\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Megace ES: 625 mg/5 mL (150 mL) [contains alcohol, usp, sodium benzoate; lemon-lime flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Megace Oral: 40 mg/mL (240 mL [DSC]) [lemon-lime flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/mL (10 mL, 240 mL, 480 mL); 400 mg/10 mL (10 mL); 625 mg/5 mL (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25047968\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:0em;\">Tablet, Oral, as acetate: 160 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192298\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Shake suspension well before use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The 625 mg/5 mL suspension may be administered without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132799\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192297\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anorexia or cachexia:</b> <i>Suspension:</i> Treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Treatment of AIDS-related weight loss should only be initiated after addressing the treatable causes (eg, malignancy, infection, malabsorption, endocrine disease, renal disease, psychiatric disorder) for weight loss. Megestrol is not intended to prevent weight loss.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer:</b> <i>Tablet:</i> Treatment (palliative) of advanced breast cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial cancer:</b> <i>Tablet:</i> Treatment (palliative) of advanced endometrial carcinoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25572898\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Treatment of cancer-related cachexia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192337\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Megace may be confused with Reglan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Megestrol may be confused with mesalamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Megestrol is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to an increased risk of thrombotic events and potentially death in older adults, with minimal effects on weight (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Megestrol is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192285\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypertension (4% to 8%), cardiomyopathy (1% to 3%), chest pain (1% to 3%), edema (1% to 3%), palpitations (1% to 3%), peripheral edema (1% to 3%), cardiac failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (3% to 10%), pain (4% to 6%, similar to placebo), insomnia (1% to 6%), abnormality in thinking (1% to 3%), confusion (1% to 3%), convulsions (1% to 3%), depression (1% to 3%), hypoesthesia (1% to 3%), neuropathy (1% to 3%), paresthesia (1% to 3%), carpal tunnel syndrome, lethargy, malaise, mood changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash (6% to 12%), alopecia (1% to 3%), dermatological disease (1% to 3%), diaphoresis (1% to 3%), pruritus (1% to 3%), vesicobullous dermatitis (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia (6%), decreased libido (1% to 5%), albuminuria (1% to 3%), gynecomastia (1% to 3%), increased lactate dehydrogenase (1% to 3%), adrenocortical insufficiency, amenorrhea, Cushing's syndrome, diabetes mellitus, hot flash, HPA-axis suppression, hypercalcemia, weight gain (not attributed to edema or fluid retention)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea (10%, similar to placebo), flatulence (6% to 10%), vomiting (4% to 6%), nausea (4% to 5%), dyspepsia (2% to 3%), abdominal pain (1% to 3%), constipation (1% to 3%), oral moniliasis (1% to 3%), sialorrhea (1% to 3%), xerostomia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Impotence (4% to 14%), urinary incontinence (1% to 3%), urinary tract infection (1% to 3%), urinary frequency (1% to 2%), breakthrough bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia (1% to 3%), sarcoma (1% to 3%), tumor flare</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatomegaly (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Candidiasis (1% to 3%), herpes virus infection (1% to 3%), infection (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Amblyopia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough (1% to 3%), dyspnea (1% to 3%), pharyngitis (1% to 3%), pulmonary disorder (1% to 3%), pneumonia (1%), hyperventilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Decreased glucose tolerance, thromboembolic phenomena (including deep vein thrombosis, pulmonary embolism, thrombophlebitis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to megestrol or any component of the formulation; known or suspected pregnancy (suspension).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for progestins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192282\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May suppress hypothalamic-pituitary-adrenal (HPA) axis during chronic administration; consider the possibility of adrenal suppression in any patient receiving or being withdrawn from chronic therapy when signs/symptoms suggestive of hypoadrenalism are noted (during stress or in unstressed state). Laboratory evaluation and replacement/stress doses of rapid-acting glucocorticoid should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cushing syndrome: Has been reported with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS-related cachexia: The effects on HIV viral replications are unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: New-onset diabetes mellitus and exacerbation of preexisting diabetes have been reported with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Use with caution in patients with a history of thromboembolic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females: Vaginal bleeding or discharge may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant drug interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concentrated suspension: Megace ES suspension in not equivalent to other formulations on a mg-per-mg basis; Megace ES suspension 625 mg/5 mL is equivalent to megestrol acetate suspension 800 mg/20 mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299657\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192287\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9603&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Megestrol may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192290\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (tablet) / X (suspension) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4627707\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were demonstrated in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Use during pregnancy is contraindicated (suspension) and appropriate contraception is recommended in women who may become pregnant. In clinical studies, megestrol was shown to cause breakthrough vaginal bleeding in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4627709\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Megestrol is present in breast milk. Information is available from five breastfeeding women, ~8 weeks postpartum, who were administered megestrol 4 mg in combination with ethinyl estradiol 50 mcg daily for contraception. Maternal serum and milk samples were obtained over 5 days, beginning 10 days after therapy began. The highest concentrations of megestrol were found at the samples taken 3 hours after the maternal dose. Mean concentrations of megestrol were 6.5 ng/mL (maternal serum; range: 3.7 to 10.8 ng/mL), 4.6 ng/mL (foremilk; range: 1.1 to 12.7 ng/mL), and 5.6 ng/mL (hindmilk; range: 1.2 to 18.5 ng/mL) (Nilsson 1977). Due to the potential for adverse reaction in the breastfed newborn, the manufacturer recommends discontinuing breastfeeding while receiving megestrol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192292\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs of thromboembolic events; blood pressure, weight; serum glucose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192281\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A synthetic progestin with antiestrogenic properties which disrupt the estrogen receptor cycle. Megestrol interferes with the normal estrogen cycle and results in a lower LH titer. May also have a direct effect on the endometrium. Megestrol is an antineoplastic progestin thought to act through an antileutenizing effect mediated via the pituitary. May stimulate appetite by antagonizing the metabolic effects of catabolic cytokines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192300\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Breast or endometrial cancer: At least 2 months of continuous therapy; Weight gain: 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (to free steroids and glucuronide conjugates)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Suspension: 20 to 50 hours; Tablet: Mean: 34.2 hours (range: 13 to 105 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Suspension: 5 hours; Tablet: 2.2 hours (range: 1 to 3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (57% to 78%; 5% to 8% as metabolites); feces (8% to 30%) within 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524681\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Megace ES Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">625 mg/5 mL (150 mL): $1,205.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Megestrol Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (240 mL): $143.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">625 mg/5 mL (150 mL): $898.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Megestrol Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $69.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $123.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192303\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apegestrol (BD);</li>\n      <li>Apetrol (KR);</li>\n      <li>Endace (IN);</li>\n      <li>Maygace (ES);</li>\n      <li>Megace (AR, AT, AU, BD, BE, BG, CL, CN, CO, CZ, DK, EE, EG, FR, GB, GR, HK, HN, HR, IE, IT, JO, JP, KR, KW, LB, LT, LU, MY, NL, NO, NZ, PK, PL, PT, QA, RU, SA, SG, SI, TH, TR, TW, UY, VN);</li>\n      <li>Megace ES (BB);</li>\n      <li>Megace Oral (BB);</li>\n      <li>Megaplex (ID, PH, RU, TH);</li>\n      <li>Megase (VE);</li>\n      <li>Megastrol (PY);</li>\n      <li>Megatus (TW);</li>\n      <li>Megejohn (TW);</li>\n      <li>Megesia (KR);</li>\n      <li>Megesin (HK, RO);</li>\n      <li>Megestat (BR, DE);</li>\n      <li>Megex-I (PE);</li>\n      <li>Megostat (AU, HR);</li>\n      <li>Mestrel (MX, TH);</li>\n      <li>Mestrol (TW);</li>\n      <li>Norea (ES);</li>\n      <li>Onistrol (LK);</li>\n      <li>Tracetate (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9137798\"></a>Beller E, Tattersall M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. <i>Ann Oncol</i>. 1997;8(3):277-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9137798/pubmed\" target=\"_blank\" id=\"9137798\">9137798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farrar DJ, &quot;Megestrol Acetate: Promises and Pitfalls,&quot; <i>AIDS Patient Care STDS</i>, 1999, 13(3):149-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/10375262/pubmed\" target=\"_blank\" id=\"10375262\">10375262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lentz SS, Brady MF, Major FJ, et al, &ldquo;High-Dose Megestrol Acetate in Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 1996, 14(2):357-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/8636744/pubmed\" target=\"_blank\" id=\"8636744\">8636744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8478668\"></a>Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. <i>J Clin Oncol</i>. 1993;11(4):762-767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/8478668/pubmed\" target=\"_blank\" id=\"8478668\">8478668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2193166\"></a>Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. <i>J Natl Cancer Inst</i>. 1990;82(13):1127-1132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/2193166/pubmed\" target=\"_blank\" id=\"2193166\">2193166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megace (megestrol acetate oral suspension) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megace ES (megestrol acetate suspension) [prescribing information]. Spring Valley, NY: Par Pharmaceuticals Companies, Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megace OS (megestrol acetate suspension) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megestrol tablets [prescribing information]. Columbus, OH: Roxane Laboratories; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megestrol tablets [product monograph]. Toronto, Ontario, Canada: AA Pharma, Inc.; May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson S, Nygren KG, Johansson ED. Megestrol acetate concentrations in plasma and milk during administration of an oral contraceptive containing 4 mg megestrol acetate to nursing women. <i>Contraception</i>. 1977;16(6):615-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/606501/pubmed\" target=\"_blank\" id=\"606501\">606501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23543530\"></a>Ruiz Garcia V, L&oacute;pez-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. <i>Cochrane Database Syst Rev</i>. 2013;3:CD004310.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/23543530/pubmed\" target=\"_blank\" id=\"23543530\">23543530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strang P, &ldquo;The Effect of Megestrol Acetate on Anorexia, Weight Loss and Cachexia in Cancer and AIDS Patients,&rdquo; <i>Anticancer Res</i>, 1997, 17(1B):657-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9066597/pubmed\" target=\"_blank\" id=\"9066597\">9066597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9708631\"></a>Vadell C, Segu&iacute; MA, Gim&eacute;nez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. <i>Am J Clin Oncol</i>. 1998;21(4):347-351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9708631/pubmed\" target=\"_blank\" id=\"9708631\">9708631</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9603 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192314\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F192315\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F192330\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F192316\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F192317\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F192318\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16317898\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192294\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F192278\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F25047968\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F192298\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132799\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F192297\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25572898\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F192337\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192285\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192282\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299657\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F192287\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192290\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4627707\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4627709\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F192292\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192281\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F192300\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524681\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F192303\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9603|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=megestrol-acetate-patient-drug-information\" class=\"drug drug_patient\">Megestrol acetate: Patient drug information</a></li><li><a href=\"topic.htm?path=megestrol-acetate-pediatric-drug-information\" class=\"drug drug_pediatric\">Megestrol acetate: Pediatric drug information</a></li></ul></div></div>","javascript":null}